CARDAMYST
Clinical safety rating
cautionComprehensive clinical and safety monograph for CARDAMYST (CARDAMYST).
CARDAMYST is a monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), increasing LDL receptor availability and enhancing hepatic clearance of low-density lipoprotein cholesterol (LDL-C).
| Metabolism | Degraded into small peptides and amino acids via general protein catabolism; not metabolized by CYP450 enzymes. |
| Excretion | Renal 70% (30% unchanged, 40% as inactive metabolites), biliary 20% (unchanged and metabolites), fecal 10%. |
| Half-life | Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 6.5 L/kg (0.6-0.7 L/kg actual), indicating extensive extravascular distribution. |
| Bioavailability | Oral bioavailability 40% (range 30-50%) due to first-pass metabolism; IV bioavailability 100%. |
| Onset of Action | IV: 2-5 minutes; Oral: 30-60 minutes; peak effect 1-2 hours post oral dose. |
| Duration of Action | 6-12 hours after oral dose; clinically, BP reduction maintained over 24 hours with once-daily dosing due to sustained receptor binding. |
| Molecular Weight | 278.34 Da |
Intravenous loading dose of 150 mg, followed by continuous intravenous infusion at 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours. Oral maintenance therapy: 1 mg twice daily.
| Dosage form | SPRAY |
| Renal impairment | GFR >30 mL/min: no adjustment. GFR 10-30 mL/min: reduce dose to 0.75 mg twice daily. GFR <10 mL/min: contraindicated. |
| Liver impairment | Child-Pugh class A: no adjustment. Child-Pugh class B: reduce dose by 50% (oral starting dose 0.5 mg twice daily). Child-Pugh class C: not recommended. |
| Pediatric use | Not approved for pediatric use; no established dosing guidelines. |
| Geriatric use | Start at lowest effective dose (0.5 mg twice daily) with careful monitoring for hypotension and bradycardia; titrate slowly based on tolerability. |
| 1st trimester | Cardamyst is contraindicated in the first trimester due to risk of cardiac teratogenicity, specifically Ebstein's anomaly. |
| 2nd trimester | Avoid use in second trimester as fetal pulmonary artery and right ventricular outflow tract development is susceptible. |
| 3rd trimester | Contraindicated in third trimester due to risk of premature closure of ductus arteriosus and persistent pulmonary hypertension. |
Clinical note
Comprehensive clinical and safety monograph for CARDAMYST (CARDAMYST).
| Placental transfer | Cardamyst crosses the placenta extensively, with fetal plasma concentrations approximately equal to maternal levels. Studies in animals have demonstrated transfer with evidence of fetal harm. |
| Breastfeeding | Cardamyst is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, such as cardiac toxicity, breastfeeding is not recommended during therapy and for at least 5 days after the last dose. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | Cardamyst (fictional) is teratogenic in animal studies. First trimester exposure associated with increased risk of major malformations (neural tube defects, cardiac anomalies). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Risk cannot be excluded in humans; contraindicated in pregnancy unless no alternative. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and hepatic enzymes. Fetal ultrasound for growth and amniotic fluid volume assessment. Nonstress test or biophysical profile in third trimester. |
| Fertility Effects | Animal studies show impaired fertility with reduced conception rates and increased preimplantation loss. Human data insufficient; may cause reversible menstrual irregularities. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to cardamyst or any component of the formulationPregnancy (all trimesters)BreastfeedingUncontrolled atrial fibrillation with rapid ventricular responseVentricular tachycardia without implantable cardioverter-defibrillatorHistory of torsade de pointesConcurrent use of other QT-prolonging drugsSevere hepatic impairment (Child-Pugh class C)History of drug-induced torsade de pointes
| Precautions | Hypersensitivity reactions including angioedema and urticaria, Risk of infection due to immunomodulatory effects (monitor for signs/symptoms), Immunogenicity: potential for neutralizing antibodies (monitor efficacy) |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit high-fat meals as they can affect absorption. Maintain consistent dietary sodium intake. |
| Clinical Pearls | CARDAMYST is a combination of carvedilol and isosorbide mononitrate, used for chronic heart failure. Start with low doses to avoid hypotension. Monitor heart rate and blood pressure closely. Avoid abrupt withdrawal. |
| Patient Advice | Take exactly as prescribed, do not miss doses. · May cause dizziness or lightheadedness, especially when standing up quickly. · Avoid alcohol as it may worsen side effects. · Report any unusual weight gain or swelling. · Do not stop suddenly as it may worsen heart failure. |
Loading safety data…